Artículos de revistas
A Randomized Controlled Trial To Evaluate The Effectiveness Of 2 Regimens Of Fixed Iodine ( 131i) Doses For Graves Disease Treatment
Registro en:
Clinical Nuclear Medicine. , v. 37, n. 3, p. 241 - 244, 2012.
3639762
10.1097/RLU.0b013e31823ea6e0
2-s2.0-84857224936
Autor
Santos R.B.
Romaldini J.H.
Ward L.S.
Institución
Resumen
AIM:: To investigate the effectiveness of 2 fixed iodine (I) doses for the treatment for Graves hyperthyroidism and their impact on eye disease. METHODS:: We prospectively examined 76 patients who received a fixed dose of 370 MBq (group 1) and 52 patients who received 555 MBq I (group 2). Patients were followed up for 12 months and considered in remission when they were in a stable euthyroid or hypothyroid state in the absence of antithyroid drugs 12 months after I administration. Eight patients with active eye disease received a daily dose of 0.5 mg/kg prednisone per kilogram of body weight at the time of radioiodine therapy for 1 month. RESULTS:: The remission rate obtained was similar in groups 1 (73.7%) and 2 (80.8%; P = 0.35). Hypothyroidism was diagnosed in 56.5% of the 370-MBq group and 71.1% of the 555-MBq group patients (P = 0.13). There was no correlation among clinical features, thyroid uptake, antibody levels, serum hormones levels, and outcome. However, logistic regression analysis demonstrated that patients with large thyroid glands had 2.4 times less chance to go into remission (odds ratio; 95% confidence interval = 1.18-4.96). None of the patients developed eye disease during any fixed-dose treatment regimen or worsened their previously diagnosed ophthalmopathy. CONCLUSIONS:: Fixed doses of 370 MBq and 555 MBq I provided similar remission rates; however, outcome was influenced by the thyroid size. We propose that 370 MBq I should be the routine treatment dose for all Graves disease patients, reserving a dose of 555 MBq I to palpable large goiters, without any additional concern to eye disease. © 2012 by Lippincott Williams & Wilkins. 37 3 241 244 Romaldini, J.H., Case selection and restrictions recommended to patients with hyperthyroidism in South America (1997) Thyroid, 7 (2), pp. 225-228 Zakavi, S.R., Mousavi, Z., Davachi, B., Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule (2009) Nucl Med Commun, 30, pp. 169-175 Ward, L.S., Castelo Filho, A., Menabó, E., Cost/effective ratio in the treatment of Basedow-Graves disease (1986) AMB Rev Assoc Med Bras., 32, pp. 147-154 Cruz Júnior, A.F., Takahashi, M.H., Albino, C.C., Clinical treatment with antithyroid drugs or iodine-131 therapy to control the hyperthyroidism of Graves' disease: A cost-effectiveness analysis (2006) Arq Bras Endocrinol Metabol., 50, pp. 1096-1101 Dietlein, M., Moka, D., Dederichs, B., Cost-effectiveness analysis: Radioiodine or antithyroid medication in primary treatment of immune hyperthyroidism (1999) Nuklearmedizin, 38, pp. 7-14 Jarløv, A.E., Hegedüs, L., Kristensen, L.O., Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? (1995) Clin Endocrinol., 43, pp. 325-329 Leslie, W.D., Ward, L., Salamon, E.A., Ludwig, S., Rowe, R.C., Cowden, E.A., A randomized comparison of radioiodine doses in graves' hyperthyroidism (2003) Journal of Clinical Endocrinology and Metabolism, 88 (3), pp. 978-983. , DOI 10.1210/jc.2002-020805 Bahn, R.S., Burch, H.B., Cooper, D.S., The American thyroid association and American association of clinical endocrinologists taskforce on hyperthyroidism and other causes of thyrotoxicosis. Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American thyroid association and American association of clinical endocrinologists (2011) Thyroid, 21, pp. 593-646 Ceccarelli, C., Bencivelli, W., Vitti, P., Grasso, L., Pinchera, A., Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: A 20 years' restrospective study (2005) Clinical Endocrinology, 62 (3), pp. 331-335. , DOI 10.1111/j.1365-2265.2005.02218.x Mourits, M.Ph., Prummel, M.F., Wiersinga, W.M., Koornneef, L., Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy (1997) Clinical Endocrinology, 47 (1), pp. 9-14 De Rooij, A., Vandenbroucke, J.P., Smit, J.W., Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: Systematic review and meta-analysis (2009) Eur J Endocrinol, 161, pp. 771-777 Tallstedt, L., Lundell, G., Blomgren, H., Bring, J., Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? (1994) European Journal of Endocrinology, 130 (5), pp. 494-497 Träisk, F., Tallstedt, L., Abraham-Nordling, M., Thyroid study group of TT 96. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131 (2009) J Clin Endocrinol Metab., 94, pp. 3700-3707 Acharya, S.H., Avenell, A., Philip, S., Et Alburr, J., Bevan, J.S., Abraham, P., Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: A systematic review (2008) Clin Endocrinol, 69, pp. 943-950 Canadas, V., Vilar, L., Moura, E., Evaluation of radioiodine therapy with fixed doses of 10 and 15 mCi in patients with Graves' disease (2007) Arq Bras Endocrinol Metabol, 51, pp. 1069-1076 Santos, R.B., Romaldini, J.H., Ward, L.S., Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid Graves' disease patients (2004) Thyroid, 14, pp. 523-527